

**FDA/FCHR COLLABORATIVE PUBLIC MEETING ON LONG-TERM SAFETY CONCERNS
ASSOCIATED WITH CCR5 ANTAGONIST DEVELOPMENT**

MAY 31, 2006
WASHINGTON, DC

THE GEORGE WASHINGTON UNIVERSITY MARVIN CENTER
The Marvin Center, 800 21st Street, N.W., Washington, DC 20052

8:30 – 10:30	SESSION I: CHEMOKINE ANTAGONISTS IN DEVELOPMENT: CURRENT STATUS	Chair: Debra Birnkrant
8:30	WELCOME & INTRODUCTIONS	Debra Birnkrant
8:35	CHEMOKINE RECEPTORS AND ANTAGONISTS: SUMMARY OF CLINICAL EXPERIENCE ✓ Tropism assay, tropism changes, and safety issues	Roy Gulick
9:05	RECAP OF FCHR CHEMOKINE ANTAGONIST WORKING GROUP MEETINGS	Veronica Miller
9:20	REGULATORY PERSPECTIVE ✓ Current Requirements for Approval ✓ Proposed Monitoring plans ✓ Summary of Responses	Scott Proestel
09:50 10:10	LONG-TERM SAFETY MONITORING ✓ ACTG experience ✓ Long-term safety monitoring of HIV patients in an observational setting	Dan Kuritzkes Jens Lundgren
10:30- 10:45	BREAK	
	SESSION II: PANEL DISCUSSION AND PUBLIC RESPONSE	Chairs: Roy Gulick & Joe Eron
10:45– 12:30	PANEL A: MONITORING & SAFETY	Moderator: Roy Gulick <u>Panelists:</u> Judith Millard John Doweiko Tom Gegeny David Haerry Katherine Laessig Richard Little Howard Mayer William Olson Paul Skolnik Kate Squires Robert Yarchoan
12:30 –	LUNCH	

1:30		
1:30 – 3:00	PANEL B: VIRAL TROPISM & RESISTANCE	Moderator: Joe Eron <u>Panelists:</u> Stephen Becker Richard Colvin Lynda Dee Steve Deeks Jim Demarest Wayne Greaves John Moore Lisa Naeger Neil Parkin Jonathan Schapiro Mani Subramanian
3:00-4:00	PANEL C: CLINICAL EFFICACY AND STRATEGY	Moderators: Roy Gulick and Joe Eron <u>Panelists from Panel A & B plus pediatrics</u> Andy Wiznia
4:00 – 4:15	WRAP-UP	